A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing–remitting multiple sclerosis

Background: Mycophenolate mofetil (MMF, CellCept®) has been utilized as an antirejection agent in transplant recipients and in patients with myriad autoimmune disorders including multiple sclerosis (MS). Objective: To investigate radiographic and clinical safety involving monotherapy use of daily or...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Frohman, Elliot M., Cutter, Gary, Remington, Gina, Gao, Hongjiang, Rossman, Howard, Weinstock-Guttman, Bianca, Durfee, Jacqueline E., Conger, Amy, Carl, Ellen, Treadaway, Katherine, Lindzen, Eric, Salter, Amber, Frohman, Teresa C., Shah, Anjali, Bates, Angela, Cox, Jennifer L., Dwyer, Michael G., Stüve, Olaf, Greenberg, Benjamin M., Racke, Michael K., Zivadinov, Robert
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2010
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002613/
https://ncbi.nlm.nih.gov/pubmed/21180633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609353354
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki